Structure of Mepolizumab
CAS No.: 196078-29-2
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Mepolizumab is a humanized IgG1 monoclonal antibody that prevents IL-5 from binding to its receptor by binding to IL-5. Mepolizumab has potential for research in eosinophilic diseases such as severe eosinophilic asthma.
Synonyms: SB 240563
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 196078-29-2 |
M.W : | 146.24 kDa |
SMILES Code : | NONE |
Synonyms : |
SB 240563
|
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319 |
Precautionary Statements: | P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT00244686 | Hypereosinophilic Syndrome | NO_LONGER_AVAILABLE | - | - | |
NCT03453021 | Asthma; Eosinophilic | COMPLETED | 2017-10-31 | University Hospital Grenoble, ... More >>La Tronche, 38700, France Less << | |
NCT06348173 | Asthma | COMPLETED | 2023-11-30 | H?pital du Sacré-Coeur de Mont... More >>réal, Montréal, Quebec, H4J 1C5, Canada Less << | |
NCT06107101 | Chronic Rhinosinusitis With Na... More >>sal Polyps Less << | PHASE4 | NOT_YET_RECRUITING | 2025-01-01 | St. Paul's Sinus Centre, Vanco... More >>uver, British Columbia, V6Z 1Y6, Canada Less << |
NCT04512521 | Asthma; Eosinophilic | RECRUITING | 2025-08-25 | Hannover Medical School, Hanov... More >>er, Niedersachsen, 30625, Germany Less << | |
NCT05063981 | Asthma|Nasal Polyps|Sinusitis ... More >>Chronic Less << | RECRUITING | 2025-12-24 | Istituti Clinici Scientifici M... More >>augeri IRCCS, Telese Terme, BN, 82037, Italy Less << | |
NCT04550780 | Asthma | COMPLETED | 2023-07-31 | Uh Montpellier, Montpellier, 3... More >>4280, France Less << | |
NCT04305678 | Eosinophilic Fasciitis | PHASE1 | WITHDRAWN | 2023-02-15 | - |
NCT03021304 | Asthma | PHASE3 | COMPLETED | 2017-08-08 | GSK Investigational Site, Birm... More >>ingham, Alabama, 35243, United States|GSK Investigational Site, Los Angeles, California, 90025, United States|GSK Investigational Site, Cincinnati, Ohio, 45231, United States|GSK Investigational Site, Orangeburg, South Carolina, 29118-2040, United States|GSK Investigational Site, Sainte-Foy, Quebec, G1V 4G5, Canada|GSK Investigational Site, St. Charles-Borromee, Quebec, J6E 2B4, Canada|GSK Investigational Site, Amsterdam, 1105 AZ, Netherlands|GSK Investigational Site, Leeuwarden, 8934 AD, Netherlands|GSK Investigational Site, Zwolle, 8025 AB, Netherlands|GSK Investigational Site, Ekaterinburg, 620109, Russian Federation|GSK Investigational Site, Moscow, 123095, Russian Federation|GSK Investigational Site, Saint-Petersburg, 198328, Russian Federation|GSK Investigational Site, Link?ping, SE-581 85, Sweden|GSK Investigational Site, Lund, SE-221 85, Sweden|GSK Investigational Site, Stockholm, SE-141 86, Sweden Less << |
NCT00266565 | Hypereosinophilic Syndromes|Eo... More >>sinophilic Gastroenteritis|Churg-Strauss Syndrome|Eosinophilic Esophagitis Less << | PHASE1|PHASE2 | COMPLETED | 2025-04-05 | Cincinnati Children's Hospital... More >> Medical Center, Cincinnati, Ohio, 45229-3039, United States Less << |
NCT05895929 | Chronic Rhinosinusitis With Na... More >>sal Polyps|Chronic Rhinosinusitis (Diagnosis) Less << | EARLY_PHASE1 | RECRUITING | 2025-06-26 | Johns Hopkins Bayview Medical ... More >>Center, Baltimore, Maryland, 21117, United States|Johns Hopkins Hospital, Baltimore, Maryland, 21287, United States Less << |
NCT05139381 | Asthma in Children | ACTIVE_NOT_RECRUITING | 2026-03-12 | King's College Hospital, Londo... More >>n, SE5 9RS, United Kingdom Less << | |
NCT04965636 | Hypereosinophilic Syndrome | PHASE3 | RECRUITING | 2024-09-16 | GSK Investigational Site, Roch... More >>ester, Minnesota, 55905, United States|GSK Investigational Site, Cincinnati, Ohio, 45229, United States|GSK Investigational Site, Cleveland, Ohio, 44106, United States|GSK Investigational Site, Charleston, South Carolina, 29425, United States|GSK Investigational Site, Caba, Buenos Aires, C1028AAP, Argentina|GSK Investigational Site, Florencio Varela, Buenos Aires, 1888, Argentina|GSK Investigational Site, Florida, Buenos Aires, 1602, Argentina|GSK Investigational Site, Quilmes, Buenos Aires, 1878, Argentina|GSK Investigational Site, Sao Paulo, S?o Paulo, 05410-002, Brazil|GSK Investigational Site, Sorocaba, S?o Paulo, 18040-425, Brazil|GSK Investigational Site, Petach Tikva, 49202, Israel|GSK Investigational Site, Monterrey, Nuevo León, 64060, Mexico|GSK Investigational Site, Madrid, 28009, Spain|GSK Investigational Site, Ankara, 6230, Turkey|GSK Investigational Site, Izmir, 35100, Turkey|GSK Investigational Site, Kayseri, 38039, Turkey|GSK Investigational Site, London, SE5 9RS, United Kingdom Less << |
NCT01691859 | Asthma | PHASE3 | COMPLETED | 2017-05-31 | GSK Investigational Site, Long... More >> Beach, California, 90808, United States|GSK Investigational Site, Riverside, California, 92506, United States|GSK Investigational Site, Denver, Colorado, 80206, United States|GSK Investigational Site, New Haven, Connecticut, 06520, United States|GSK Investigational Site, Albany, Georgia, 31707, United States|GSK Investigational Site, Lexington, Kentucky, 40508, United States|GSK Investigational Site, Winston-Salem, North Carolina, 27103, United States|GSK Investigational Site, Cleveland, Ohio, 44195, United States|GSK Investigational Site, Hershey, Pennsylvania, 17033, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, 15213, United States|GSK Investigational Site, Nashville, Tennessee, 37212, United States|GSK Investigational Site, Mar del Plata, Buenos Aires, B7600FZN, Argentina|GSK Investigational Site, Ciudad Autónoma de Buenos Aires, C1121ABE, Argentina|GSK Investigational Site, Ciudad Autónoma de Buenos Aires, C1426ABP, Argentina|GSK Investigational Site, Mendoza, M5500CCG, Argentina|GSK Investigational Site, New Lambton, New South Wales, 2305, Australia|GSK Investigational Site, Adelaide, South Australia, 5000, Australia|GSK Investigational Site, Clayton, Victoria, 3168, Australia|GSK Investigational Site, Melbourne, Victoria, 3004, Australia|GSK Investigational Site, Nedlands, Western Australia, 6009, Australia|GSK Investigational Site, Calgary, Alberta, T2N 4Z6, Canada|GSK Investigational Site, Vancouver, British Columbia, V5Z 1M9, Canada|GSK Investigational Site, Mississauga, Ontario, L5A 3V4, Canada|GSK Investigational Site, Quebec City, Quebec, G1V 4G5, Canada|GSK Investigational Site, Puente Alto - Santiago, Región Metro De Santiago, 8207257, Chile|GSK Investigational Site, Valparaiso, Valparaíso, 2341131, Chile|GSK Investigational Site, Santiago, 8380453, Chile|GSK Investigational Site, Talcahuano, 4270918, Chile|GSK Investigational Site, Le Kremlin-Bicêtre Cedex, 94275, France|GSK Investigational Site, Marseille cedex 20, 13915, France|GSK Investigational Site, Montpellier cedex 5, 34295, France|GSK Investigational Site, Saint Pierre cedex, 97448, France|GSK Investigational Site, Ruedersdorf, Brandenburg, 15562, Germany|GSK Investigational Site, Frankfurt am Main, Hessen, 60596, Germany|GSK Investigational Site, Frankfurt, Hessen, 60596, Germany|GSK Investigational Site, Mainz, Rheinland-Pfalz, 55131, Germany|GSK Investigational Site, Luebeck, Schleswig-Holstein, 23552, Germany|GSK Investigational Site, Berlin, 10367, Germany|GSK Investigational Site, Berlin, 10717, Germany|GSK Investigational Site, Magdeburg, 39120, Germany|GSK Investigational Site, Cheongju, Chungcheongbuk-do, 361-711, Korea, Republic of|GSK Investigational Site, Suwon, Kyonggi-do, 443-721, Korea, Republic of|GSK Investigational Site, Lodz, 90-153, Poland|GSK Investigational Site, Wroclaw, 54-239, Poland|GSK Investigational Site, Bucharest, 011461, Romania|GSK Investigational Site, Bucharest, 050159, Romania|GSK Investigational Site, Iasi, 700115, Romania|GSK Investigational Site, Targu Mures, 540143, Romania|GSK Investigational Site, Barnaul, 656 045, Russian Federation|GSK Investigational Site, Chelyabinsk, 454106, Russian Federation|GSK Investigational Site, Kazan, 420008, Russian Federation|GSK Investigational Site, Moscow, 105 077, Russian Federation|GSK Investigational Site, Moscow, 123182, Russian Federation|GSK Investigational Site, Saint-Petersburg, 194354, Russian Federation|GSK Investigational Site, St'Petersburg, 191015, Russian Federation|GSK Investigational Site, Dnipropetrovsk, 49051, Ukraine|GSK Investigational Site, Donetsk, 83099, Ukraine|GSK Investigational Site, Kharkiv, 61035, Ukraine|GSK Investigational Site, Kiev, 03680, Ukraine|GSK Investigational Site, Kyiv, 03038, Ukraine|GSK Investigational Site, Leicester, Leicestershire, LE3 9QP, United Kingdom|GSK Investigational Site, London, EC1M 6BQ, United Kingdom|GSK Investigational Site, London, SW3 6HP, United Kingdom|GSK Investigational Site, Manchester, M23 9LT, United Kingdom|GSK Investigational Site, Southampton, SO16 6YD, United Kingdom Less << |
NCT02377427 | Asthma | PHASE2 | COMPLETED | 2018-01-31 | GSK Investigational Site, San ... More >>Diego, California, 92123, United States|GSK Investigational Site, Oklahoma City, Oklahoma, 73112, United States|GSK Investigational Site, Medford, Oregon, 97504, United States|GSK Investigational Site, Madison, Wisconsin, 53792-9988, United States|GSK Investigational Site, Fukuoka, 811-1394, Japan|GSK Investigational Site, Hiroshima, 720-8520, Japan|GSK Investigational Site, Hiroshima, 721-8511, Japan|GSK Investigational Site, Wakayama, 646-8558, Japan|GSK Investigational Site, Lodz, 90-329, Poland|GSK Investigational Site, Tarnow, 33-100, Poland|GSK Investigational Site, Glasgow, G514TF, United Kingdom|GSK Investigational Site, Liverpool, L12 2AP, United Kingdom|GSK Investigational Site, London, SE5 9RS, United Kingdom|GSK Investigational Site, London, SW3 6NP, United Kingdom|GSK Investigational Site, Oxford, OX3 9DU, United Kingdom|GSK Investigational Site, Sheffield, S10 2TH, United Kingdom Less << |
NCT03099096 | Asthma | PHASE3 | COMPLETED | 2017-11-30 | GSK Investigational Site, Birm... More >>ingham, Alabama, 35243, United States|GSK Investigational Site, Scottsdale, Arizona, 85251, United States|GSK Investigational Site, Los Angeles, California, 90025, United States|GSK Investigational Site, San Diego, California, 92123, United States|GSK Investigational Site, Colorado Springs, Colorado, 80907, United States|GSK Investigational Site, Aventura, Florida, 33180, United States|GSK Investigational Site, Miami, Florida, 33173, United States|GSK Investigational Site, Albany, Georgia, 31707, United States|GSK Investigational Site, Evansville, Indiana, 47713, United States|GSK Investigational Site, Baltimore, Maryland, 21236, United States|GSK Investigational Site, Saint Louis, Missouri, 63141, United States|GSK Investigational Site, Piscataway, New Jersey, 08854, United States|GSK Investigational Site, Rochester, New York, 14642, United States|GSK Investigational Site, Cincinnati, Ohio, 45231, United States|GSK Investigational Site, Medford, Oregon, 97504, United States|GSK Investigational Site, Orangeburg, South Carolina, 29118, United States|GSK Investigational Site, Woodville South, South Australia, 5011, Australia|GSK Investigational Site, Clayton, Victoria, 3169, Australia|GSK Investigational Site, Nedlands, Western Australia, 6009, Australia|GSK Investigational Site, Sherwood Park, Alberta, T8H 0N2, Canada|GSK Investigational Site, Toronto, Ontario, M5T 3A9, Canada|GSK Investigational Site, Windsor, Ontario, N8X 2G1, Canada|GSK Investigational Site, St. Charles-Borromee, Quebec, J6E 2B4, Canada|GSK Investigational Site, Ruedersdorf, Brandenburg, 15562, Germany|GSK Investigational Site, Frankfurt, Hessen, 60389, Germany|GSK Investigational Site, Leipzig, Sachsen, 04357, Germany|GSK Investigational Site, Schleswig, Schleswig-Holstein, 24837, Germany|GSK Investigational Site, Berlin, 10717, Germany|GSK Investigational Site, Berlin, 12203, Germany|GSK Investigational Site, Chelyabinsk, 454021, Russian Federation|GSK Investigational Site, Voronezh, 394066, Russian Federation|GSK Investigational Site, Link?ping, SE-581 85, Sweden|GSK Investigational Site, Lund, SE-221 85, Sweden|GSK Investigational Site, Leicester, Leicestershire, LE3 9QP, United Kingdom|GSK Investigational Site, Bradford, BD96RJ, United Kingdom|GSK Investigational Site, Oxford, OX37LE, United Kingdom|GSK Investigational Site, Plymouth, PL6 8DH, United Kingdom|GSK Investigational Site, Southampton, SO16 6YD, United Kingdom Less << |
NCT04578171 | Asthma | UNKNOWN | 2025-01-23 | - | |
NCT03306043 | Hypereosinophilic Syndrome | PHASE3 | COMPLETED | 2019-12-30 | GSK Investigational Site, La J... More >>olla, California, 92093, United States|GSK Investigational Site, New Haven, Connecticut, 06520, United States|GSK Investigational Site, Rochester, Minnesota, 55905, United States|GSK Investigational Site, Cincinnati, Ohio, 45229, United States|GSK Investigational Site, Mayfield Heights, Ohio, 44124, United States|GSK Investigational Site, Murray, Utah, 84107, United States|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, C1028AAP, Argentina|GSK Investigational Site, La Plata, Buenos Aires, Argentina|GSK Investigational Site, Mar del Plata, Buenos Aires, 7600, Argentina|GSK Investigational Site, Bruxelles, 1070, Belgium|GSK Investigational Site, Leuven, 3000, Belgium|GSK Investigational Site, Porto Alegre, Rio Grande Do Sul, 40110-160, Brazil|GSK Investigational Site, Santo André - SP, S?o Paulo, 09080-110, Brazil|GSK Investigational Site, Sorocaba, S?o Paulo, 18040-425, Brazil|GSK Investigational Site, Lille Cedex, 59037, France|GSK Investigational Site, Nantes Cedex 1, 44093, France|GSK Investigational Site, Suresnes, 92151, France|GSK Investigational Site, Toulouse Cedex 9, 31059, France|GSK Investigational Site, Mannheim, Baden-Wuerttemberg, 68167, Germany|GSK Investigational Site, Fulda, Hessen, 36043, Germany|GSK Investigational Site, Hannover, Niedersachsen, 30625, Germany|GSK Investigational Site, Kirchheim unter Teck, 73230, Germany|GSK Investigational Site, Napoli, Campania, 80131, Italy|GSK Investigational Site, Firenze, Toscana, 50134, Italy|GSK Investigational Site, Guadalajara, Jalisco, 44100, Mexico|GSK Investigational Site, Monterrey, Nuevo León, 64060, Mexico|GSK Investigational Site, Villahermosa, Tabasco, 86035, Mexico|GSK Investigational Site, Krakow, 31-066, Poland|GSK Investigational Site, Lodz, 90-153, Poland|GSK Investigational Site, Bucharest, 010306, Romania|GSK Investigational Site, Targu Mures, 540327, Romania|GSK Investigational Site, Moscow, 125167, Russian Federation|GSK Investigational Site, Saint-Petersburg, 197341, Russian Federation|GSK Investigational Site, Barcelona, 08036, Spain|GSK Investigational Site, Valencia, 46026, Spain|GSK Investigational Site, Leicester, LE3 9QP, United Kingdom Less << |
Tags: Mepolizumab | SB 240563 | IL | IL-5/monoclonal antibody | Immunology/Inflammation | Parkinson'S Disease and Alzheimer'S Disease | Cancer Stem Cells | PPAR Signaling Pathway | Pyroptosis | Human Inhibitory Monoclonal Antibody | 196078-29-2
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL